Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
DEXFERRUM (iron dextran) is an intravenous iron replacement therapy indicated for patients with iron deficiency anemia who cannot tolerate or absorb oral iron supplements. It works by providing bioavailable iron through a dextran carrier complex that replenishes depleted iron stores.
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely in transition mode with reduced hiring and focus shifting toward lifecycle extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Working on DEXFERRUM represents a mature product career opportunity focused on defending market share and optimizing profitability rather than driving growth or innovation. Limited linked job postings indicate constrained headcount and reduced hiring momentum, making this a stabilization rather than expansion role.
Worked on DEXFERRUM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo